ticagrelor 60mg BID for 30 Days and ASA 75 - 150 mg once daily

clopidogrel 75mg OD for 30 Days and ASA 75 - 150 mg once daily

Diabetes Mellitus

Microvascular Coronary Artery Disease

Ticagrelor

Clopidogrel

Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.

30-d Rand, Eval-blind, Controlled, Multi-centre, Parallel, ph III Study to Evaluate Effect of a Low Maint Dose Ticagrelor Regimen vs Standard Dose Clopidogrel on Coronary Flow Reserve in DM Patients With Impaired Microvascular Function Without Prior MI or Stroke Undergoing ePCI.

Difference in mean of individual absolute change from baseline to 30 days in Coronary Flow Velocity Reserve (CFR) in the mid-distal segment of the left anterior descending (LAD) coronary artery under adenosine infusion measured by Transthoracic Doppler Echocardiography (TDE) between the two arms

Difference in mean of individual absolute change from baseline at 30 days in:
- LAD hyperemic mean diastolic flow velocity

Difference in mean of individual absolute change from baseline at 30 days
- LAD resting mean diastolic flow velocity

Region Skane

IHF GmbH - Institut für Herzinfarktforschung

Hippocrates Research

IRW consulting AB

AstraZeneca

Ischemic Heart Disease

Chronic Total Occlusion of Coronary Artery

Percuteneous Coronary Intervention

Initiation and titration of optimal medical therapy in the control arm.

Optimal Medical Therapy

Aarhus University Hospital

Rigshospitalet

Gentofte Hospital

Odense University Hospital

Zealand University Hospital

North-Estonia Medical Centre

Helsinki University Central Hospital

Kuopio University Hospital

Lahti Central Hospital

Heart Hospital Tampere

Turku University Hospital

Cardiovascular Institute, Groupe Hospitalier Mutualiste

Institut Arnault Tzanck

Bergen University Hospital - Haukeland

Hospital Germans Trias I Pujol

Hospital Galdakao

Hospital del Mar

Hospital Vall de Hebron

Hospital Clinic

Hospital de Bellvitge

Hospital Universitario Clinico San Carlos

Hospital la Paz

Hospital Universitari de Tarragona Joan XXIII

Sahlgrenska University Hospital

Gävle Hospital

Stockholm South Central Hospital (Södersjukhuset)

Belfast Health and Social Care Trust, Department of Cardiology

University Hospital Bristol

Barts Health NHS

St George's University Hospital

ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO

International Randomized Trial on the Effect of Revascularization or Optimal Medical Therapy of Chronic Total Coronary Occlusions With Myocardial Ischemia - ISCHEMIA-CTO Trial

Evald Hoej Christiansen

Consultant MD PhD

Aarhus University Hospital Skejby

Patients with known or suspected coronary artery disease undergoing clinically ordered stress cardiac magnetic resonance imaging.

Coronary Artery Disease

Regadenoson

1740 W Taylor Street, 2nd Floor, Cardiac Imaging

Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements

Assessment and Prognostic Significance of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements During Regadenoson Stress Cardiac Magnetic Resonance

Afshin Farzaneh-Far

Assistant Professor of Clinical Medicine

University of Illinois at Chicago

Astellas Pharma Inc

Rest and vasodilator stress Rb-82 images and N-13 ammonia images will be taken according to standard clinical imaging protocol. Each of these two imaging studies require the injection of Rb-82 and N-13 ammonia by intravenous administration (IV) in the patient's arm.

Volunteers not excluded by abnormal rest/stress imaging with Rb-82, will begin F-18 FDG protocol.

Volunteers not excluded by abnormal rest/stress imaging with N-13 ammonia, will begin F-18 FDG protocol.

Heart Disease

Intravenous administration of Rb-82. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For Rb-82 images, 40 mCi (millicuries are a measurement of radioactivity) will be used. Acquisition time for both rest and stress studies should take about 30 min.

Rb-82 Pet scans

Volunteers undergoing the F-18 FDG protocols will undergo: (1) glucose loading protocol for "viability protocol imaging" with the hyperinsulinemic euglycemic clamp according to standard procedures in our laboratory, and (2) "inflammation protocol imaging" using a high fat preparatory diet and three sub-therapeutic heparin doses (10 units / kg each) according to standard laboratory procedure. When metabolically prepared with the viability protocol and the inflammation protocol (two separate days), 10 mCi (millicuries) of F-18 FDG will be administered IV per FDG protocols, via heparin lock. 40-60 minutes after FDG injections PET imaging will be performed according to standard clinical imaging protocol.

F-18 FDG Pet scans

Intravenous administration of N-13. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For N-13 ammonia images, 20 mCi (millicuries) will be used. Acquisition time for both rest and stress studies should take about 30 min.

N-13 ammonia Pet scans

Regadenoson is used as a stressor; but not to study its effects.

University of Michigan Hospital

Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers

Evaluation of the Normal Distribution of Rubidium-82(Rb-82), Nitrogen-13 (N-13)Ammonia, and Fluorine-18 Fluorodeoxyglucose (F-18FDG) in Normal Volunteers

Normal healthy volunteers will undergo PET imaging during vasodilator pharmacologic stress with regadenoson and at rest with Rb-82 and or N-13 ammonia and or at rest with F-18FDG. Participants will have either rest and stress Rb-82 and rest and stress N-13 ammonia or one of these stress tests and F-18 FDG imaging.

James R. Corbett, M.D.

Principal Investigator

University of Michigan

Subjects will have a PET scan after IV administration of a radio-labelled tracer, Rb-82 and N-13 or injection of F-18 FDG

rubidium

infarction

rubidium/infarction

Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.

ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO

Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements

Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht